cyrilzakka/clinical-trials huggingface dataset:
Gene Expression Profiling of Metastatic Breast Cancer Predict the Therapeutic Response to Chemotherapy

The investigators want to develop a gene expression profile the for prediction the chemotherapeutic response of patients with metastatic breast cancer.

1. Metastatic breast cancer tissue is obtained from core needle biopsies pretreatment and is flash frozen and stored at -70℃ until processing.
2. After patients received docetaxel combination thiotepa for two cycles, response is assessed using Response Evaluation Criteria in Solid Tumor Group (RECIST) guidelines. Degree of response is used to divide the cancers into two groups-sensitive and resistant tumours.
3. The gene expression in metastatic breast cancer tissue sample is detected by microarray to screen gene markers that are differently expressed between groups
4. Statistical analysis is performed using unsupervised hierarchical cluster.

Eligibility Criteria:
Inclusion Criteria:

* Patients should be histologically confirmed with metastatic breast cancer;
* Patients who had completed the planned chemotherapy regimen with no major protocol violation;
* an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;
* At least one measurable lesion;
* Normal cardiac, hepatic, renal and bone marrow functions;
* Life expectancy ≥3 months;
* Discontinuity of previous chemotherapy for a minimum of 4 weeks.

Exclusion Criteria:

* previous history of other malignancies;
* previous surgery history on the needle biopsy organ;
* Central nervous system metastases;
* Serious or uncontrolled concurrent medical illness.
The Impact of a Colonoscopy Monitoring Program on Endoscopists' Performance

The goal of this clinical trial is to learn if colonoscopy monitoring program works to adenoma detection rate in endoscopists. It will also learn about the impact on sessile serrated lesion detection rate, adenomas per colonoscopy, sessile serrated lesions per colonoscopy, advanced adenoma detection rate. The main questions it aims to answer are:

Does colonoscopy monitoring program effect on adenoma detection rate in endoscopists?

Participants will:

Receive result of colonoscopy monitoring program or not every 3 months for 1 year


Eligibility Criteria:
Inclusion Criteria:

* Endoscopists with at least 1 year of colonoscopy experience

Exclusion Criteria:

* Endoscopists with less than 1 year of colonoscopy experience
Severity of Scorpion Sting in Relation to Hematological Parameters

The aim of this study is to investigate the relationship between severity of envenomation and hematological parameter by detectig initial mean platelet volume (MPV), neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) in pediatric patients presenting with a scorpion sting.

Scorpion stings are common emergency events in many parts of the world. It is common in tropical and subtropical regions. In our locality, Upper Egypt, scorpions still represent and a life hazard, especially to children .The clinical manifestations of scorpionism are due to complex interactions between sympathetic and parasympathetic stimulation.This leads to increased release of neurotransmitters and mediators, resulting in a cascade of pathological events, involving the nervous system, the cardiovascular and the respiratory system, eventually leading to death.Scorpionism results in hormonal and biochemical changes with significant release of catecholamines, increased angiotensin II and inhibition of insulin secretion .The symptoms and signs of envenomation are usually more severe in children, especially younger ones. Local pain represent 66 to 90 percent of stings which is practically immediate, of varying intensity ranging from mild to very intense. It is characterized by tingling, burning, or stinging. Regardless of the severity of envenoming, pain and paresthesia may persist at the site or at the affected limb for several days .Systemic effects become apparent in 10 to 33 percent of patients.After envenomation, symptoms may begin immediately and typically progress to maximum severity within 5 hours. The clinical effects of stings are characterized, cardiovascular, neurological and gastrointestinal effects .Cardiovascular effects are atrial tachycardia, ventricular extrasystoles, T-wave inversion, ST-T wave changes, bundle-branch block. Catecholamine-induced myocarditis and myocardial ischemia results in pulmonary edema and cardiogenic shock.Cardiovascular effects are atrial tachycardia, ventricular extrasystoles, T-wave inversion, ST-T wave changes, bundle-branch block. Catecholamine-induced myocarditis and myocardial ischemia results in pulmonary edema and cardiogenic shock..Gastrointestinal effects: are vomiting, abdominal pain and diarrhea. Also acute pancreatitis has been reported.Cardiovascular toxic effects and acute pulmonary edema are the most important complications of scorpion stings and the most frequent cause of death in the first 24 hours after the sting .Gastrointestinal effects: are vomiting, abdominal pain and diarrhea. Also acute pancreatitis has been reported.Cardiovascular toxic effects and acute pulmonary edema are the most important complications of scorpion stings and the most frequent cause of death in the first 24 hours after the sting .

Eligibility Criteria:
Inclusion Criteria:

* a) Patients presented with scorpion sting

Exclusion Criteria:

* All other envenomation or intoxications
Noninvasive Brain Stimulation for Stroke

Noninvasive brain stimulations will be used in acute and chronic stroke patients to improve a variety of functions.

Noninvasive brain stimulations (NIBS) will be used in acute and chronic stroke patients to improve a variety of functions such as motor functions, cognitive functions, ...

NIBS will be applied in a placebo-controlled, double-blind, randomised fashion. Behavioural data will be collected before and after NIBS, as well as brain functional imaging data.

Eligibility Criteria:
Inclusion Criteria:

* stroke with at least slight deficit

Exclusion Criteria:

* epilepsy
* contraindication to tDCS and/or to fMRI
* presence of metal in the head
* unability to understand / complete behavioural tasks
* chronic intake of alcohol or recreative drugs
* major health condition
* presence of pacemaker
* pregnancy
Genetic Study of Atrial Fibrillation: Focusing on Renin-Angiotensin System and C-Reactive Protein Genes

Multi-locus and multi-gene studies of atrial fibrillation, focusing on renin-angiotensin system genes and C reactive protein gene


Eligibility Criteria:
Inclusion Criteria:

* Patients with atrial fibrillation

Exclusion Criteria:

* Patients with atrial fibrillation who are reluctant for the study
Reproductibility of Lumbar Spine ADC Based on Different Post-processing Softwares

Lumbar spine bone marrow is well explored in Magnetic Resonance Imaging (MRI) but some bone marrow diseases are hard to analyze with this method. Furthermore, there is heterogeneity in normal bone marrow, called apparent diffusion coefficient (ADC). Histological and technical factors appear to be the cause, but the possible influence of the employed post-processing software has never yet been evaluated. The purpose of this study is to determine if there is variability in lumbar bone ADC related to the post-processing software.

Lumbar spine bone marrow is well explored in MRI. Some bone marrow diseases are hard to analyze in conventional MRI, and diffusion-weighted imaging (DWI) could be an additional diagnostic feature. However, according to the literature, there is heterogeneity in normal bone marrow of the quantitative parameter that it provides, called apparent diffusion coefficient (ADC). Histological and technical factors appear to be the cause, but the possible influence of the employed post-processing software has never yet been evaluated. The purpose of this study is to determine if there is variability in lumbar bone ADC related to the post-processing software.

Eligibility Criteria:
Inclusion Criteria:

* Consecutive patients undergoing lumbar spine MRI at University Hospital of Saint-Etienne

Exclusion Criteria:

* \<18 years old
Effectiveness of Prophylactic Bolus Ephedrine Versus Norepinephrine for Management of Post Spinal Hypotension

This study was conducted to compare the effectiveness of ephedrine versus norepinephrine for management of hypotension after spinal anesthesia for mothers undergoing elective cesarean section


Eligibility Criteria:
Inclusion Criteria:

* ASA class II and ages ranging from 18-35 years were included in the study

Exclusion Criteria:

* pregnant women with preeclampsia/eclampsia, baseline hypertension (SBP\> 140 mm Hg), BMI\> 30 kg/m2, failed spinal, spinal anaesthesia converted to general anaesthesia, contraindication for spinal anaesthesia and mother with cardiovascular, renal or hepatic disease.
Pembrolizumab in First-Line Treatment of Advanced-Stage Classical Hodgkin Lymphoma

The primary objective of this trial is to estimate efficacy of the novel regimen. The primary endpoint is the 1-year PFS rate after treatment with one dose of pembrolizumab followed by four to six cycles of chemo-immunotherapy with P-BrECADD, and PET-guided radiotherapy as per standard of care


Eligibility Criteria:
Main Inclusion Criteria:

* age 18-60
* advanced stage classical Hodgkin Lymphoma
* no previous treatment for cHL

Main Exclusion Criteria:

* Nodular lymphocyte-predominant Hodgkin lymphoma or composite lymphoma
* Chemotherapy or radiotherapy in medical history
* Prior or concurrent disease that prevents treatment according to protocol
Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment

Incidence of cancer in 75+ years old is 16,500 new cases per year, more than fifty percent of people with cancerThey are very few therapeutic trials dedicated. Oncologists hesitate to treat them because they are either afraid of inducing toxicity or of breaking down quality of life. Consequently, we decided to launch a protocol with both oncologists and geriatricians which principal aim is to find out if geriatric assessment data can help to better predict for chemotherapy toxicity, loss of autonomy and survival. We plan to accrue 360 patients diagnosed for cancer, including digestive, pulmonary, prostate, lymphoma, bladder, ovary cancer for whom first-line chemotherapy is planned. Patients are initially classified according to usual methods of medical oncology practice into three groups: patients who can receive standard treatment, reduced standard treatment or treatment adapted to the frail condition. Around Aquitaine, , we organised seven teams composed of one geriatrician and one nurse. Two kind of teams were activated: one which cover ten treatment sites in Bordeaux area and six sedentary teams which worked half a day a week in designated hospitals . Geriatric evaluation included test of cognitive functions (MMS), nutritional status (MNA), co-morbidity (CIRS-G), mobility (Get up and Go), activities (ADL;IADL), quality of life (QLQ-C30), depression (GDS-15) and Lachs-Balducci screening. Patients have four geriatric evaluations : before treatment, day 1 cycle 2, day 1 cycle 4, day 1 cycle 7 and/or end of chemotherapy. Since September 2002, 177 patients have been included, 112 have finished: 47.3% have received four evaluations, 16.1% died before the end of protocol, 14.3% stopped because they were in progression and changed their treatment, 11.6% met administrative problem that didn't allow all evaluations, 7.1% declined after inclusion and 3.6% finished their treatment before. The following results have been obtained: before treatment, 73% of these patients were at risk of undernutrition (MNA\< 23.5), about 1/3 had one or more inability or a risk of falls (38% IADL\<6, 29% get up and go\>20seconds, 27% ADL\>1, 34% PS\<1), 28% of them had altered cognitive functions (MMS\<24), 29% were depressive (GDS-15\>6), 25% thought they had poor quality of life (QLQ-C30\<4). Protocol will be closed in September 2005.


Eligibility Criteria:
Inclusion criteria:

* Age ≥ 70 years
* First line of chemotherapy
* Cancer previously mentioned
GPX-100 in Treating Patients With Solid Tumors

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase I trial to study the effectiveness of GPX-100 in treating patients who have solid tumors.

OBJECTIVES: I. Determine the maximum tolerated dose of GPX-100 in outpatients with incurable, solid tumors who are not candidates for effective systemic therapy. II. Evaluate and quantify the toxicity of GPX-100 in this patient population. III. Identify any changes in disease status in this patient population.

OUTLINE: This is an open label, multicenter, dose escalation study. Patients receive GPX-100 IV once every 3 weeks. Patients receive 2 courses of treatment in the absence of disease progression or dose limiting toxicity. Treatment may continue for up to 6 courses (4 courses with prior doxorubicin) in patients with responding or non-progressing disease. One patient is entered at each of the first 3 dose levels. Cohorts of 3-6 patients are entered at subsequent dose levels. The maximum tolerated dose of GPX-100 is defined as the dose at which no more than 2 instances of dose limiting toxicity are observed in 6 patients.

PROJECTED ACCRUAL: A maximum of 30 patients will be accrued for this study.

Eligibility Criteria:
DISEASE CHARACTERISTICS: Incurable, solid tumors in patients who are not candidates for effective systemic therapy Progressive disease defined as a 25% increase in diameter of measurable lesions or appearance of new lesions

PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Zubrod 0-2 Life expectancy: Greater than 16 weeks Hematopoietic: WBC at least 4000/mm3 Platelet count at least 125,000/mm3 Hemoglobin at least 8 g/dL Hepatic: Bilirubin within normal limits SGOT no greater than 1.5 times normal (2.5 times normal with disease involvement) Alkaline phosphatase no greater than 2.5 times normal PT or PTT less than 1.5 times normal Renal: Creatinine no greater than 1.5 times normal Creatinine clearance at least 60 mL/min Cardiovascular: No history of congestive heart failure, active ischemic heart disease, or uncontrolled hypertension No myocardial infarction within the past 6 months Other: Not pregnant or nursing (negative pregnancy test required) Fertile patients must use effective contraception No weight loss of 10% or more in the past 3 months No frequent vomiting No severe anorexia

PRIOR CONCURRENT THERAPY: Biologic therapy: Prior biologic therapy allowed No concurrent immunotherapy Chemotherapy: At least 4 weeks since prior chemotherapy (6 weeks for mitomycin or nitrosoureas) and recovered No greater than 300 mg/m2 cumulative dose of doxorubicin No concurrent chemotherapy Endocrine therapy: At least 4 weeks since prior hormone therapy No concurrent anticancer hormone therapy Concurrent corticosteroids allowed Radiotherapy: At least 4 weeks since prior radiotherapy and recovered No concurrent radiotherapy Surgery: Not specified Other: At least 4 weeks since prior investigational drug therapy No other concurrent investigational therapy
Group-based Cognitive-behavioral Therapy for Adults With Attention-deficit/Hyperactivity Disorder Inattentive-type

The newly developed CBT for ADHD inattentive-type (ADHD-I) protocol is tested for feasibility and acceptability in a pilot study with a single group design. The study also evaluates measurements and recruiting possibilities, and effects of the intervention. Research hypotheses include: 1. There is a basis for recruiting ADHD-I patients for participation in an RCT at psychiatric outpatient units, 2. The measurements in the study are feasible and reasonable in regards to patient characteristics; that is, the patients are responding to the questionnaires as intended, 3. The CBT for ADHD-I intervention is feasible in terms of treatment completion, compliance to home assignments, and credibility and relevance, and is lacking of or involves a tolerable degree of adverse effects, and 4. The CBT for ADHD-I protocol reduces core symptoms of ADHD-I as well as symptoms of stress, depression, and anxiety, and improves quality of life.


Eligibility Criteria:
Inclusion Criteria:

In addition to an ADHD inattentive-type diagnosis, inclusion criteria are:

1. 18 years or older,
2. intelligence quotient above 80-85, and
3. if on medication, it needs to be well-established since three months.

Exclusion Criteria:

1. autism spectrum disorder,
2. ongoing substance use disorder,
3. difficulties in compliance with medical or other treatment,
4. social and/or psychiatric problems to such an extent that it prevents focusing on treatment, or
5. ongoing cognitive-behavioral therapy.
Quantification and Description of the Increase in Serum Troponin Following Acute Coronary Syndrome

The new assay of troponins T (highly sensitive troponins) detects concentrations much lower than before. Few data are currently available on their kinetics during acute coronary syndrome, especially in regard to the correlation with CK MB. The aim of the present study is to describe the kinetic of highly sensitive troponins in acute coronary syndrome, to correlate it with the concentration of CK MB, and possibly to evaluate their prognostic value with respect to infarct size .

Patients who meet the inclusion criteria will have a highly sensitive troponins and CKMB assays q 8hr for the first day, and q 12h for the next 2 days. If clinically not indicated, the blood sample can be cancelled at any time, as in the case of a patient with an initial suspicion of acute coronary syndrome in which the final diagnosis is something else. Only patients with a definitive myocardial infarction will be analyzed.

Subgroup analyses includes ST-elevation MI, Non ST-elevation MI, revascularization vs no revascularization, procedural myocardial infarction.

Another analysis conducted is the correlation between the values of troponin and infarct size by echocardiography (in patients who have an echocardiography 2-7 days post AND 2-6 months post myocardial infarction)

Eligibility Criteria:
Inclusion Criteria:

* \>= 18 years-old
* Clinical suspicion of an acute coronary syndrome; (will be analyzed only patients with aposteriori definitive diagnosis of unstable angina or myocardial infarction)

Exclusion Criteria:

* none
The Effect of RadiaAce Gel in the Prevention and Treatment of Radiation Dermatitis in Breast Cancer Patients

Radiation dermatitis (RD) is one of the most common side effects of Radiation therapy (RT) and 95% of patients receiving RT may experience some form of radiation dermatitis.

A wide variety of topical, oral, and intravenous agents are used to prevent/treat Radiation dermatitis but currently there is no gold standard in the prevention and management of this condition and no treatment can be explicitly recommended.

RadiaAce Gel is a wound dressing Hydrogel (Acemannan Hydrogel) for the management of RD which provides optimal moist wound environment necessary to the healing process.

Based on its composition as well as the supporting data on safety and performance of the functional ingredient Acemannan in wound healing, RadiaAce may well be suited to complement the prevention and therapy of radiation dermatitis.

The primary aim of the study is to evaluate the safety and performance of RadiaAce as compare to Biafine in reducing the proportion of breast cancer patients that experience grade 2 or higher RD as measured by the RTOG scoring system


Eligibility Criteria:
Inclusion Criteria:

1. Female patients
2. Age \> 18
3. Patients with histologically-confirmed diagnosis of breast cancer
4. Patients after breast lumpectomy and that scheduled to receive radiotherapy
5. Patients to receive minimum of 40.05 Gy to primary field
6. Must be able to comply with treatment schedule
7. Study-specific signed informed consent prior to randomization

Exclusion Criteria:

1. Inflammatory or connective tissue disorders of the skin
2. Mental incompetence, including psychological or addictive disorders which would preclude completion of questionnaires
3. Previous radiation therapy to the breast
4. Tumour involvement of the skin
5. Rash, ulceration or open wound in treatment field
6. Known skin allergy or sensitivity to Aloe Vera or Biafine
7. Current lactation
8. Pregnancy
9. Any other reason that, in the opinion of the investigator, prevents the subject from
Ultrasonography in Norwegian Emergency Department Patients With Suspected Covid-19 Infection

In light of the ongoing COVID-19 epidemic in Norway, it is paramount to develop and utilize clinical tools for assessing and risk stratifying patients with suspected coronary infection in the emergency departments. Diagnostic use of ultrasound in viral pneumonias, including COVID-19 has proved to be very useful. The use of ultrasound will assist in quick detection of lung pathology compatible with increasing severity of the COVID-19 disease. At the same time, the use of ultrasound diagnostics in the emergency department could improve logistics and reduce potential exposure of the corona virus to other health personnel.

The purpose of the study is to assess whether ultrasound findings correlates with physical examination, labs, and other imaging diagnostics in patients with suspected or diagnosed COVID-19 disease, as well as assessing whether ultrasound diagnostics can assist in risk stratification. The project is conducted as a prospective multicenter study where ultrasound diagnostics will be performed on patients with suspected coronary infection in the emergency departments. Data collection takes place as part of the daily clinical evaluation of acute patients in the emergency departments. The project is planned to be completed towards the end of 2025.


Eligibility Criteria:
Inclusion Criteria:

- All emergency department patients with suspected or diagnosed COVID-19.

Exclusion Criteria:

* Negative screening for COVID-19
* recent negative COVID-19 test
* no indication for isolation in the Emergency Department
Safety and Gastrointestinal Effects of Intravenous Methylnaltrexone

This study evaluates the safety of multiple doses of IV MNTX in normal healthy adults.


Eligibility Criteria:
Inclusion Criteria:

1. Must be male or non-pregnant female volunteers
2. Must be 18 to 65 yrs of age
3. Must have no significant active disease states

Exclusion Criteria:

1. History or current evidence of disease (cardiovascular, respiratory, endocrine, renal, hepatic, hematological, or psychiatric)
2. Illicit drug users
3. Subjects who received an experimental new drug in the past 30 days
4. Subjects with any laboratory findings outside normal limits